Business
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
MINNEAPOLIS and BRISBANE, Australia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) in symptomatic severe aortic stenosis patients with small aortic annuli (aortic annulus area 396 + 37 mm2).
About this update from Anteris Technologies Global Corp.
[{"type":"image","alt":"Anteris Technologies Global Corp.","displaySize":"","headline":null,"caption":"Anteris Technologies Global Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ebb91cde24fc8bfaa2bbd449d64df87a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8tNysNEA0DQBTcTu5RQZLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ebb91cde24fc8bfaa2bbd449d64df87a","width":300,"height":83}},"lazy":false},{"type":"text","content":"MINNEAPOLIS and BRISBANE, Australia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced one-year clinical outcomes for the DurAVR® Transcatheter Heart Valve (THV) in symptomatic severe aortic stenosis patients with small aortic annuli (aortic annulus area 396 + 37 mm2). The DurAVR® THV System demonstrated single digit mean gradients and large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality at one year, with low prosthesis-patient mismatch at 30 days.","length":740,"tagName":"p"},{"type":"text","content":"One-year Results Highlights","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"DurAVR® THV delivered a favorable hemodynamic profile sustained to one-year, with an EOA of 2.1 + 0.2 cm2 and a mean pressure gradient (MPG) of 8.6 + 2.6 mmHg. ","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"At one-year, clinical safety outcomes were positive with no valve related mortality and no moderate or severe paravalvular leak (PVL).","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"At 30-days, prosthesis-patient mismatch* was just 1.5%, compared with 11.2% to 35.3%1 for current commercial devices, highlighting a meaningful reduction in a key predictor of valve failure and disease progression.","length":214,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":527,"olType":false},{"type":"text","content":"“With small annuli patients, even minor hemodynamic inefficiencies can limit long-term outcomes, which is why optimi...